DiaMedica Therapeutics (DMAC) Non-Current Assets (2017 - 2026)

DiaMedica Therapeutics' Non-Current Assets history runs 10 years deep, the most recent figure standing at $717000.0 for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 49.08% year-over-year to $717000.0 in Q1 2026; TTM through Mar 2026 was $717000.0, a 49.08% decrease from a year earlier, with the FY2025 full-year figure at $742000.0, down 57.23% from the prior year.
• Non-Current Assets retreated to $717000.0 in Q1 2026 per DMAC's latest filing, from $742000.0 in the prior quarter.
• Across five years, Non-Current Assets topped out at $20.8 million in Q2 2023 and bottomed at $85000.0 in Q2 2022.
• The 5-year median for Non-Current Assets is $742000.0 (2025), against an average of $2.6 million.
• Across the five-year window, Non-Current Assets surged 24392.94% in 2023 and slumped 91.46% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $560000.0 in 2022, then fell by 13.39% to $485000.0 in 2023, then soared by 257.73% to $1.7 million in 2024, then sank by 57.23% to $742000.0 in 2025, then decreased by 3.37% to $717000.0 in 2026.
• Per Business Quant, the three latest DMAC Non-Current Assets figures stand at $717000.0 (Q1 2026), $742000.0 (Q4 2025), and $824000.0 (Q3 2025).